Malaria parasites (Plasmodium spp.) remain one of the most severe and common causes of human disease (White, Pukrittayakamee, et al., 2014). Although interventions against malaria parasites have seen significant successes over the last 30 years (WHO 2015a), resistance has evolved to every antimalarial drug in widespread use (Hyde, 2005; White, 2004; WHO 2015a). In many cases, this resistance has been attributed to “classical” resistance mechanisms (sensu Schneider et al., 2012), including target site mutations or detoxification mechanisms (Hyde, 2002, 2005). However, changes in parasite behaviour, metabolism or life history, that is, “nonclassical” resistance mechanisms (Schneider et al., 2012), offer additional threats to drug efficacy.